# Metformin and Nightly Fasting in Women With Early Breast Cancer

> **NCT05023967** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 120 (actual)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Breast Ductal Carcinoma In Situ
- Invasive Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Extended Release Metformin Hydrochloride
- **OTHER:** Monitoring
- **OTHER:** Nutritional Assessment
- **OTHER:** Short-Term Fasting

## Key facts

- **NCT ID:** NCT05023967
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-04
- **Primary completion:** 2025-12-09
- **Final completion:** 2026-12-16
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05023967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05023967, "Metformin and Nightly Fasting in Women With Early Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05023967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*